archive-com.com » COM » M » MYOFIBRILLAR-MYOPATHIES.COM

Total: 34

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Pages - donations
    a DFG multilocation research unit Home Home Donations Quick Launch Overview Projects Project Leaders Team Publications Symposia News Job Offers Donations Contact Useful Links Imprint Search DONATIONS If you wish to donate the FOR 1228 DFG multilocation research unit please

    Original URL path: http://www.myofibrillar-myopathies.com/Pages/donations.aspx (2016-02-17)
    Open archived version from archive


  • Pages - contactus
    Useful Links Imprint Search CONTACT US Speaker of the DFG Research Group FOR 1228 Prof Dr med Rolf Schröder Institut für Neuropathologie Schwabachanlage 6 91054 Erlangen Fon 49 9131 85 34782 Fax 49 9131 85 26033 Email rolf schroeder uk erlangen de Vice Speaker of the DFG Research Group FOR 1228 Prof Dr phil Dieter Fürst Institut für Zellbiologie Universität Bonn Ulrich Haberland Strasse 61a 53121 Bonn Fon 49 228

    Original URL path: http://www.myofibrillar-myopathies.com/Pages/contactus.aspx (2016-02-17)
    Open archived version from archive

  • Pages - usefullinks
    accessible mode Home Sign In Molecular Pathogenesis of Myofibrillar Myopathies FOR 1228 a DFG multilocation research unit Home Home Useful Links Quick Launch Overview Projects Project Leaders Team Publications Symposia News Job Offers Donations Contact Useful Links Imprint Search Muskeldystrophie

    Original URL path: http://www.myofibrillar-myopathies.com/Pages/usefullinks.aspx (2016-02-17)
    Open archived version from archive

  • Pages - imprint
    Schröder Neuropathology Institute Head Hospital University Hospital Erlangen Director of the Institute of Neuropathology Prof Dr med Ingmar Blümcke Schwabachanlage 6 91054 Erlangen Porter 49 9131 85 26032 Secretary 49 9131 85 26031 Fax 49 9131 85 26033 Prof Dr med Heinrich Iro is acting on behalf of the University Hospital Erlangen responsible for medical law purposes Sales tax identification number DE 248558812 The University Hospital Erlangen is a public institution with legal capacity acted on behalf of Prof Dr med Heinrich Iro Board of Directors Prof Dr med Heinrich Iro Chairman Ärztlicher Direktor Alfons Gebhard Commercial Manager Reiner Schürfer Director for Care and Support P rof Dr med Dr h c Jürgen Schüttler Dean of the Medical Faculty Supervisory authority Bavarian M inistry of S tate for Science Research and Art Salvatorstraße 2 80333 München Authorised to represent for the DFG Research Group FOR 1228 Prof Dr Rolf Schröder Email rolf schroeder uk erlangen de Phone 49 9131 85 34782 Fax 49 9131 85 26033 Web site editor Stefanie Dettmer Phone 09131 85 44579 Email stefanie dettmer uk erlangen de Webmaster Siegfried Lüders Phone 09131 85 46394 E Mail sharepoint uk erlangen de Displayer The DFG Research Group FOR

    Original URL path: http://www.myofibrillar-myopathies.com/Pages/imprint.aspx (2016-02-17)
    Open archived version from archive

  • Search Center
    content Turn off more accessible mode Home Sign In Molecular Pathogenesis of Myofibrillar Myopathies FOR 1228 a DFG multilocation research unit Home All Sites Selected Tab People Unselected Tab Advanced

    Original URL path: http://www.myofibrillar-myopathies.com/SearchCenter/Pages/default.aspx (2016-02-17)
    Open archived version from archive

  • Pages - moreproject1
    lateral sclerosis ALS variant In the first funding period we generated and characterized a series of VCP p97 mutant Dictyostelium strains characterized a VCP p97 haploinsufficient mouse model and identified and characterized novel and disease relevant VCP p97 binding partners In the proposed work program for the second funding period we will extend our studies on VCP p97 with particular emphasis on the molecular basis of IBMPFD employing a broad

    Original URL path: http://www.myofibrillar-myopathies.com/Pages/moreproject1.aspx (2016-02-17)
    Open archived version from archive

  • Pages - moreproject2
    FLNC mutations we have provided comprehensive analyses of associated myopathological characteristics and biochemical pathomechanisms The first major goal of the proposed project is to obtain deeper insight into the pathological consequences of FLNC mutations and to test therapeutic approaches based on results of the first funding period To address this issue we will characterize newly identified aggregate components and filamin C ligands in the context of their disease involvement and

    Original URL path: http://www.myofibrillar-myopathies.com/Pages/moreproject2.aspx (2016-02-17)
    Open archived version from archive

  • Pages - moreproject3
    is one of the major components of the extra sarcomeric cytoskeleton During embryogenesis and later stages of development this system is enforced and regionally functionalized by additional IF proteins namely vimentin synemin and syncoilin as these proteins all colocalize either with the entire filament or at strategically important sites such as costamers Whereas vimentin appears to form authentic copolymers with desmin the situation with synemin and syncoilin is not clear For synemin we have evidence that it does not form the principal molecular complex of IFproteins i e the coiled coil neither on its own nor in complex with vimentin or desmin Instead it binds with high affinity to forming filaments According to the domain organization of syncoilin which deviates considerably from that of standard IF proteins we expect a similar molecular scenario for this protein too Therefore we want to investigate the interaction of desmin with both synemin and syncoilin at the molecular level employing analytical ultracentrifugation and chemical cross linking techniques For this purpose we will generate from these two proteins specific recombinant subdomains and determine their binding properties to desmin Starting from this investigation we will determine the minimal peptides that still bind to desmin and determine

    Original URL path: http://www.myofibrillar-myopathies.com/Pages/moreproject3.aspx (2016-02-17)
    Open archived version from archive



  •